What are the main evidence limits for Thymosin Beta-4?
Full-length thymosin beta-4, recombinant products, topical formulations, and TB-500 are not interchangeable evidence entities.
DIRECT ANSWER
Thymosin Beta-4 evidence limits.
Full-length thymosin beta-4, recombinant products, topical formulations, and TB-500 are not interchangeable evidence entities.
Reviewed August 8, 2026. Each statement links to its evidence record, followed by the primary and official sources used for this answer.
Full-length thymosin beta-4, recombinant products, topical formulations, and TB-500 are not interchangeable evidence entities.
Open evidence recordPhase 1 systemic exposure and small phase 2 topical ophthalmic studies exist, but no broad recovery indication is established.
Open evidence recordEvidence-depth scores do not establish effectiveness, safety, product quality, or personal suitability.
Open evidence recordPRIMARY & OFFICIAL SOURCES
Sources for this answer.
3 source records, with duplicates removed.